What are the effective options for the combination of acotinib/cancostat?

Acalabrutinib, as a highly selective Bruton's tyrosine kinase (BTK) inhibitor, has been widely used to treat chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B cell-related malignancies. With the continuous development of cancer treatment, monotherapy is gradually transforming into combination treatment regimens to improve efficacy and prolong patient survival. Combination regimens with acotinib are emerging as an effective treatment option, particularly in some patients with refractory or relapsed hematological malignancies.

The combination regimen of acotinib has achieved significant clinical efficacy, especially when used in combination with other targeted drugs or chemotherapy drugs. For example, acotinib is often used in combination with CD20 antibodies (such as rituximab/Rituximab) to enhance its anti-tumor effect. This combination is commonly used to treat patients with chronic lymphocytic leukemia (CLL), especially those who cannot tolerate chemotherapy or immunotherapy. Through this combination treatment, it is possible to increase the anti-tumor effect of the treatment and improve the patient's quality of life while reducing side effects.

The advantage of combined treatment with acotinib and rituximab is that they have different mechanisms of action and can complement each other. Acotinib prevents the growth and spread of B cells by inhibiting the BTK signaling pathway, while rituximab directly kills tumor cells by targeting the CD20 antigen on the surface of B cells. The combined use of the two makes the treatment effect more significant, especially for those patients with relapsed or drug-resistant CLL, which can significantly improve the patient's response rate and survival.

In some cases, acotinib can also be used in combination with traditional chemotherapy drugs such as cyclophosphamide. Although targeted therapy has gradually become the mainstream treatment of hematological tumors, in some specific cases, chemotherapy combined with targeted drug therapy is still part of the treatment plan.

Reference materials:https://www.calquence.com/